Kamada Ltd
KMDA Nasdaq· Pharmaceutical Preparations
KIRA · Stoqly’s AI analyst, in plain words
- Kamada Ltd had $180M of revenue in fiscal 2025, up 12.1% on the year before. Over five years, revenue changed +6.3% a year on average.
- Its operating margin was 14.5%, up 2.1 pts: of every 100 in sales, about 15 is left after running the business.
- Kamada Ltd made $20.2M of net profit in fiscal 2025.
- Kamada Ltd returned $11.5M to shareholders in fiscal 2025. The diluted share count rose 0.9%.
- Kamada Ltd has $65.5M more cash than debt.
Market cap
—
P/E
—
Revenue
$180M
Net income
$20.2M
Free cash flow
—
Operating margin
14.5%
Kamada Ltd in 30 seconds · fiscal 2025
Are sales growing?
+12.1%
Yes. Sales grew 12.1% last year.
Does it make a profit?
11.2%
Yes. It keeps 11.2% of every sale as profit.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
What Kamada Ltd does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 11, 2026
- Legal name
- KAMADA LTD
- CIK
- 0001567529
Kamada Ltd · KMDA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $104M | $129M | $143M | $161M | $180M |
| Revenue growth | −22.2% | 24.8% | 10.2% | 12.9% | 12.1% |
| Gross margin | 29.3% | 36.1% | 38.9% | 43.5% | 42.3% |
| Operating margin | −0.7% | 3.5% | 7.1% | 12.5% | 14.5% |
| Net income | −$2.2M | −$2.3M | $8.3M | $14.5M | $20.2M |
| Net margin | −2.2% | −1.8% | 5.8% | 9.0% | 11.2% |
| Diluted EPS | −$0.05 | −$0.05 | $0.15 | $0.25 | $0.35 |
| Cash | |||||
| Cash from operations | −$8.8M | $28.6M | $4.3M | $47.6M | $25.5M |
| Dividends paid | — | — | — | — | $11.5M |
| Share count change | 0.7% | −0.1% | 19.7% | 7.7% | 0.9% |
| Debt and strength | |||||
| Cash and short-term investments | $18.6M | $34.3M | $55.6M | $78.4M | $75.5M |
| Debt incl. finance leases | $3.8M | $26.3M | $15.0M | $10.2M | $9.9M |
| Shareholders' equity | $177M | $176M | $244M | $259M | $269M |
| Net debt / EBITDA | −39.8x | −1.4x | −3.6x | −3.2x | −2.4x |
| Current ratio | 2.4x | 1.8x | 3.4x | 3.7x | 4.1x |
| Interest coverage | −2.5x | 5.0x | 7.8x | 30.4x | 30.4x |
| Returns and quality | |||||
| Return on capital | −0.3% | 2.1% | 4.9% | 10.5% | 11.1% |
| Return on equity | −1.3% | −1.3% | 3.9% | 5.7% | 7.6% |
| Return on tangible equity | −10.0% | −8.0% | 11.3% | 6.3% | 8.5% |
| Piotroski F-score | 0 | 5 | 7 | 8 | 7 |
| Altman Z'' | 2.4 | 2.2 | 4.4 | 4.9 | 5.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$1.7M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kamada Ltd · KMDA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001567529). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.